Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes.

[Ocular Therapeutix @OCUTX]

Today, we announced positive results from the landmark SOL-1 Phase 3 superiority trial in wet AMD, an important step forward as we aim to reduce the treatment burden, with the data presentation taking place at Macula Society this month.

Learn more: https://t.co/yU7m9QxmmG

[Ocular Therapeutix @OCUTX]

Thank you to the engineers, innovators, and future leaders we met at @SWEtalk https://t.co/gXRn3tnz3p #WE26. We were proud to participate as a Patron Partner and support women driving change in the #STEM field.​
​
#WomenInEngineering #RetinaRedefined

[Ocular Therapeutix @OCUTX]

Time between injections is only part of how retina specialists judge durability in wet age-related macular degeneration (AMD). At #AAO2026, four told us what else they weigh, from sustained vision and fluid control to safety and consistency over time. #RetinaOnRecord

[Ocular Therapeutix @OCUTX]

Sawtooth. Seesaw. Different ways to describe fluid that comes and goes between treatments. At #AAO2026, we spoke with retina specialists about how they consider this pattern when evaluating long-term control of wet AMD.​
​
#RetinaOnRecord #RetinaRedefined

[Ocular Therapeutix @OCUTX]

At @saryv 2026, we’ll share updates from our clinical programs and exchange perspectives with the retina community on the future of long-term retinal disease management.​
​
#SARyV #RetinaRedefined

[Ocular Therapeutix @OCUTX]

For many people with #WetAMD, staying on therapy means frequent injection visits, often with a caregiver’s support. At @RetinaSociety, we asked what happens when that schedule becomes difficult to sustain, and what it can mean for vision over time.​
​
#RetinaOnRecord

[Ocular Therapeutix @OCUTX]

What does long-term success in wet age-related macular degeneration (AMD) look like? At #AAO2026, we sat down with a group of retina specialists to explore their perspectives on disease control and the importance of maintenance over time.​
​
#RetinaOnRecord #RetinaRedefined

[Ocular Therapeutix @OCUTX]

How long does a #WetAMD treatment need to last before it counts as meaningfully durable?​ We asked five retina specialists at @RetinaSociety. The range in their answers speaks to how expectations around durability are evolving.​
​
#RetinaOnRecord #RetinaSociety #RetinaRedefined

[Ocular Therapeutix @OCUTX]

What does meaningful durability really mean in #WetAMD care? And what happens when treatment burden gets in the way? At @RetinaSociety's Annual Meeting, five retina specialists weighed in on the questions shaping care today.​
​
#RetinaOnRecord #RetinaRedefined

[Ocular Therapeutix @OCUTX]

A superiority trial is designed to establish that one investigational treatment demonstrates better outcomes than an established therapy. At @asrsdocs, @ArshadKhanani explained why superiority sets a high bar. ​
​
Learn more: https://t.co/ZcKDjToZAO #ASRS2026 #WetAMD #MedEd

[Ocular Therapeutix @OCUTX]

Retina specialists discussed the importance of superiority data to understand how a potential treatment compares with current standard-of-care options for wet AMD at @asrsdocs ​

Learn more: https://t.co/FBedKS4Vgk​

#RetinaOnRecord #ASRS2026 #RetinaRedefined

[Ocular Therapeutix @OCUTX]

Retina specialists shared how filing based on a single Phase 3 clinical trial may help new treatment options reach patients sooner at @asrsdocs. Insights like these highlight the importance of our work to advance innovation for patients.​

Learn more: https://t.co/3VJCF9xGBH

[Ocular Therapeutix @OCUTX]

At @asrsdocs retina specialists reflected on how reducing treatment frequency may not only ease the burden for patients with wet AMD but could also support improved adherence and long-term visual outcomes. ​

Learn more: https://t.co/pRyhx1Xb9p ​

#RetinaOnRecord #ASRS2026

[Ocular Therapeutix @OCUTX]

At @asrsdocs retina specialists discussed why demonstrating superiority in a clinical trial can help provide confidence when evaluating treatment approaches for wet age-related macular degeneration.​

Learn more: https://t.co/puejquf1yq​

#RetinaOnRecord #ASRS2026

[Ocular Therapeutix @OCUTX]

Today we shared Q2 2026 earnings and new data on what durability could mean for people with wet AMD. We also remain on track for an AMD NDA submission in Q4 2026 following a positive FDA Type C meeting. ​
​
Learn more: https://t.co/A0GBJKkLcY
​
$OCUL #RetinaRedefined

[Ocular Therapeutix @OCUTX]

Retina specialists discussed why retinal fluid is an important marker of disease activity in wet AMD at @asrsdocs, reinforcing how reducing fluid fluctuations may help improve long-term visual outcomes.​

Learn more: https://t.co/fbPt9EAGmk​

#RetinaOnRecord #ASRS2026

[Ocular Therapeutix @OCUTX]

Retina specialists highlighted the connection between sustained disease control, reduced treatment burden, and long-term outcomes for patients with wet AMD during @asrsdocs. ​

Learn more: https://t.co/ccrhpFL56M​

#RetinaOnRecord #ASRS2026 #RetinaRedefined

[Ocular Therapeutix @OCUTX]

At @asrsdocs, retina specialists emphasized why maintaining fluid stability between treatments is an important goal in wet AMD and how sustained disease control may help support better long-term outcomes.​

Learn more: https://t.co/JDprskcIs7​

#RetinaOnRecord #ASRS2026

[Ocular Therapeutix @OCUTX]

Retina specialists at @asrsdocs discussed why sustained disease control and reduced treatment burden are important unmet needs in the future of wet age-related macular degeneration care. ​

Learn more: https://t.co/JDprskcIs7 ​

#RetinaOnRecord #ASRS2026 #RetinaRedefined

[Ocular Therapeutix @OCUTX]

At @asrsdocs, retina specialists shared how pulsatile dosing can potentially impact long-term visual outcomes for patients with wet age-related macular degeneration. ​

Learn more: https://t.co/JDprskcIs7​

#RetinaOnRecord #ASRS2026 #RetinaRedefined

[Ocular Therapeutix @OCUTX]

We’re looking forward to participating in the @HCWCO Ophthalmology Conference, where our Executive Chairman, President, and CEO Pravin Dugel, MD will discuss our clinical programs in wet AMD and diabetic retinopathy.

Learn more: https://t.co/DBD6usXFPd